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Summary.-Xeno-antiserum specific for antigenic components of bronchogenic
carcinoma was raised in rabbits, by passively immunizing them to normal human
lung antigens at the same time as immunization with a tumour extract from a
squamous-cell carcinoma. Antiserum so raised contained minimal quantities of
anti-normal antibody which could be removed by a single absorption with glutaral-
dehyde-insolubilized normal lung extract. When tested by quantitative complement
fixation with a panel of tumour extracts from surgical specimens, it was found that
the antiserum gave positive complement fixation with all squamous-cell carcinoma
extracts tested, and with some of the extracts from bronchogenic carcinomas of
differing pathological types. The antiserum was essentially negative for pooled
extracts from normal lung, liver and spleen but gave a weak positive reaction with an
extract of pooled foetal lung tissue.
PREVIOUS work in this laboratory was
directed toward determining the possible
presence in extracts from human bron-
chogenic carcinomas oftumour-associated
antigens (TAA). Attempts to raise a
tumour-specific antibody in rabbits in-
volved immunization of animals with
tumour extracts, followed by absorption
of the antiserum on immunoadsorbents of
Sepharose 4B to which normal lung com-
ponents had been attached by cyanogen
bromide (Watson, Smith and Levy, 1975).
The absorbed antiserum was used to test
for the presence ofTAA in various tumour
extracts by immunodiffusion. Although
inconclusive, the data implied not only
the presence of TAA in this group of
tumours, but also that common antigens
existed within pathological tumour types.
The experimental approach used in this
previous work and similar experiments
carried out in other laboratories (Yachi
et al., 1968; Mohr et al., 1974; Sega et al.,
1974) has obvious disadvantages when
definitive answers regarding the presence
of TAA are being sought. The over-
whelming majority of antibodies in xeno-
antisera raised to human tumour extracts
is directed toward normal components.
Extensive absorption can remove most of
these but the antiserum remaining still
has sufficient anti-normal-tissue activity
to preclude the use ofsensitive assays, and
the anti-tumour activity is inevitably
weak. At best, such antisera can be used
as indicators of quantitative or qualitative
differences between normal and tumour
tissue antigens, and unequivocal data are
impossible to achieve.
The experimental approach used in the
work reported herein involves the prin-
ciple reported some years ago by Moller
(1969) that the immune response to a
particular antigen can be effectivelv
repressed by specific passive immunization
of the recipient animal at the time of
immunization. We have found that
rabbits repeatedly immunized with a
mixture of antiserum to normal lung
components and tumour extract demon-
strate a markedly suppressed response to
normal components, while giving rise toTUMOUR-ASSOCIATED ANTIGENS IN BRONCHOGENIC CARCINOMA
antibodies which appear to be tumour
specific. The results of some such experi-
ments are reported below.
MATERIALS AND METHODS
Tissue extracts
Bronchogenic carcinoma tissues of a
variety of pathological types taken from
surgical specimens were dissected and ex-
tracted individually with 30M KCI, as
described previously (Watson et al., 1975).
An extract was made from an autopsy speci-
men from squamous cell carcinoma tissue
(C-71). This was used subsequently as the
immunogen. A pooled sample of 8 foetal
lungs were removed from 12-18-week saline-
inducedabortedfoetuses andsimilarlytreated.
Pooled tissues of normal human lung, spleen
and liver were obtained at autopsy from 13
patientsfreeofmalignantorinfectious disease.
Nearly equal amounts of tissue from each
donor were pooled before extraction. After
extraction, dialysis and centrifugation, pro-
tein determinations were carried out on each
sample, using the standard Lowry technique
with conversion to O.D. 280 nm absorption
standards, and the extracts were stored at
-20°C until required. All extracts utilized
in complement-fixation assays were thawed,
diluted to the appropriate protein concentra-
tion and heat inactivated at 56°C for 30 min
before use.
Immunization protocol
Preparation of anti-normal-lung serum.-
The pooled normal lung extract was used to
immunize a rabbit. The animal received 3
injections one week apart, each containing
3-0 mg protein in 50% complete Freund's
adjuvant. The antigen was administered
i.m. in 4 sites on each occasion. This protocol
was sufficient to raise a high-titre antiserum.
The rabbit was bled extensively from the
marginal ear vein 2 and 3 weeks after the last
immunization, and the serum was pooled and
stored at -20°C.
Immunization with tumour extract.-In
order to determine ratios of anti-normal-lung
serum to tumour extract for mixing prior to
immunization, a standard precipitin test
described previously (Gerwing and Thomson,
1968) was carried out with the anti-normal
serum and the C-71 tumour extract to deter-
mine the zone of equivalence and antibody
excess. The extract was prepared from a
squamous-cell carcinoma. A ratio in the zone
of antibody excess was selected which
involved a mixture of 4-0 ml antiserum with
8-0 mg of protein from the tumour extract
(the concentration ofC-71 extract was 4-0 mg/
ml). The mixture was incubated for 1 h at
37° and overnight at 4°C. The tube was
subsequently centrifuged to remove the
immune precipitate, and the supernatant was
used for immunization.
Rabbits were immunized initially with an
i.v. injection of 0-5 ml of alum-precipitated
material, and subsequently at intervals of 2
weeks with unaltered supernatant. Each
injection involved the administration of
1-0 ml in 2 locations-0-5 ml i.v. and 0-5 ml
i.m. Test bleeds were made before each
immunization, and the sera were monitored
initially by immunodiffusion with both
normal tissue and tumour tissue. Since no
discernible precipitin lines developed after 4
injections, subsequent monitoring of anti-
serum was carried out using a standard com-
plement-fixation assay. A total of 7 immuni-
zations were performed, and the animals were
extensively bled (40-50 ml) from the marginal
ear vein 12 days after the final injection.
Complement-fixation tests
Lyophilized guinea-pig complement (Flow
Laboratories, Rockville, Md.) was used.
Veronal buffer (Kabat and Mayer, 1961) was
used as diluent throughout. A 2% suspen-
sion of washed sheep erythrocytes was sensi-
tized by mixing with an equal volume of
1 : 100 dilution ofthe recommended standard
solution ofhaemolysin (Difco-Bacto antisheep
haemolysin) for at least 15 min. Quantitative
complement-fixation analyses were performed
by a modification ofthe method described by
Kabat and Mayer (1961). Overnight incuba-
tion at 4WC of 10-ml mixtures of complement
(C'), antigen (Ag) and antibody (Ab) along
with appropriate controls was used for the
fixation stage. The modifications were as
follows: (1) a smaller amount of complement
was used in the reaction mixtures, and the
following day, 5 dilutions from 1: 1-67 to
1: 3-75 in a total volume of 3-0 ml were
prepared. To each dilution tube, 1-0 ml of
the sensitized-erythrocyte suspension was
added, and lysis was allowed to proceed for
30 min at 37WC; (2) the lowest dilution from
the C' control mixture was assumed to
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correspond to 100% haemolysis, and was
used as a basis for calculating % haemolysis
in all other tubes; (3) for each reaction
mixture, the dilution of complement pro-
ducing 50% haemolysis (D50), was obtained
by the method of probits (Waksman, 1949);
(4) a unit of C', C'H50* was defined as the
amount of complement producing 50% lysis
of sheep erythrocytes under the conditions of
our test (this differs slightly from Kabat and
Mayer's standard C'H50).
In many of our experiments, one or both
of the antigen or antiserum solutions were
anticomplementary. Then, the amount of
complement fixed by specific antigen-anti-
body interaction, C'H*Ag+Ab is given by:
C'H Dc'rm X Vrm 5OAg+A -\Vd-t
X (D5A D5OAb
1 1
-D50C' D5oAg+Ab
where
DC'rm = dilution of complement in reaction
mixture
Vrm = volume ofreaction mixture (10 0 ml)
Vdt = final volume in each dilution tube
(4-0 ml)
D5oAg, D5oAb, D5oAg+Ab, D50c/ = the final
dilution ofcomplement causing 50%
lysis in dilution tubes from Ag
control, Ab control, Ag + Ab mix-
ture and C' control reaction mixtures
respectively (e.g. I/D50C, = 800
would be typical).
This formula is based on the assumption
that the amount of complement fixed in an
Ag-Ab mixture is the sum of the amount
fixed by specific Ag-Ab interaction plus the
amounts non-specifically inactivated by Ag
and Ab alone. This may not be justified
(Wadsworth, Maltaner and Maltaner, 1931).
In the series of experiments reported here,
the antiserum was absorbed once with
insolubilized normal-lung antigens. In pre-
vious studies (Purssell, Levy and Lymburner,
unpublished) we have found that antiserum
absorbed in this manner did not give rise to
appreciable non-specific interactions with
complement and antigens, so for the purposes
of these studies, we have considered
C'H*oAg+Ab values of below 0-2 to be
insignificant, since this was the maximum
reactivity noted with non-immune absorbed
rabbit serum with lung extracts and com-
plement.
Immunoadsorbents
Animmunoadsorbent was prepared by the
insolubilization of normal-lung extracts with
glutaraldehyde, according to the method of
Avrameus and Ternyck (1969) with the
following modifications. To 50-0 ml of
normal-lung extract containing 29 mg pro-
tein/ml was added 4 0 ml of 1 OM acetate
buffer, pH 5 0. The pH was adjusted to
pH 5 0 using I ON acetic acid. Six ml of25%
glutaraldehyde was added dropwise to the
material, with constant stirring. Cross-
linking was allowed to continue at room
temperature for 3 h, after which the pre-
paration was centrifuged at 8000 g for 30 min.
The insoluble material was resuspended in
0O2M phosphate buffer, pH 7 0, and subjected
tohigh-speed blending, following which it was
centrifuged again at 8000 g. The process of
homogenizing and centrifuging was repeated
x 3, after which the immunoadsorbent was
stored at 40C in physiological saline. This
quantity of adsorbent was used to adsorb
between 10 0 and 12-0 ml of serum.
Adsorption was carried out by mixing the
solid pellet with the serum and stirring for
24 h at 4°C. After adsorption the mixture
was centrifuged at 8000 g and the serum taken
off and stored at - 20°C.
RESULTS
The immunization protocols used here
did not stimulate sufficient antibody
formation to be detectable by immuno-
diffusion. In fact, only after 5 injections
was antibody to either normal or tumour
tissue detectable by complement fixation.
Serum taken after the 6th and 7th
injections appeared to be stablized, and
the subsequent work was carried out on
these samples.
When anti-C-71 was titrated at a
1/100 dilution with varying concentrations
of C-71, C-53 (a squamous-cell carcinoma
extract from an autopsy specimen) and
normal-lung extract, two discrete peaks of
fixation were observed (Fig. 1). While it
is clear that some anti-normal activity
was present in this serum, the titres were
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low enough that a single adsorption with
insolubilized normal lung tissue was suffi-
cient to remove all anti-normal activity
while retaining considerable amounts of
anti-tumour reactivity. Results of assays
carried out with the absorbed antiserum
at 1/50 are shown in Fig. 2.
Since the absorbed antiserum appeared
to cross-react effectively with both squa-
mous-cell carcinoma extracts, but not
with normal lung, a series of tests were
run on other squamous-cell carcinoma
extracts as well as on a pool of normal
spleen, normal liver and foetal lung
extracts. The results are shown in Table
I. These data imply that the antiserum
reacts positively with all squamous-cell
extracts, possibly at a low level with
foetal lung, but not with normal lung,
spleen or liver. In order to determine
whether this antibody, apparentlydirected
to an antigenic component common to
squamous-cell carcinoma, would also react
with lung tumours ofdiffering pathologies,
further tests were run on a number of
other surgical specimens. The results are
shown in Table II. It can be seen that
while some of these tumour extracts
reacted positively with the antiserum,
others did not. Whether these results
imply quantitative or qualitative differ-
ences in those tumour or normal tissue
extracts which appear to be non-reactive
with the antiserum, remains to be clarified.
DISCUSSION
The results reported here constitute
preliminary evidence that xeno-antiserum
to human TAA may be raised with relative
ease by suppressing the response to
normal tissue components by passive
immunization with anti-normal-tissue
antiserum simultaneously with immuniza-
tion with tumour extracts. We have
further data showing that this method is
applicable to other human tumours and
that the minimal anti-normal response
observed in this study can be abrogated
by increasing the ratio of anti-normal
antiserum to tumour extract in the
immunizing preparation (Purssell, Levy
and Lymburner, unpublished).
The antiserum obtained by this pro-
cedure showed specific reactivity with all
the extracts tested from individual sur-
gical specimens of squamous-cell carci-
noma. The levels of reactivity varied to
some extent, but this is not surprising
considering the crudeness of the antigen
preparations under test.
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TABLE I.-Titration ofAbsorbed anti-C-71 at a Dilution of 1/50 with Individual Extracts
ofSquamous-cell Carcinoma and Pools ofTissuefrom Foetal Lung, Normal Lung, Normal
Spleen and Normal Liver
Tissue type
Squamous-cell carcinoma extracts
C-71
C-53
C-74
C-57
C-87
C-76
C-75
C-69
C-90
Foetal lung (pool)
Normal lung (pool)
Normal spleen (pool)
Normal liver (pool)
C'HsoAg+Ab at various antigen concentrations with
absorbed antiserum at 1/50
r, A
I
- 1A - Z - 160 ,g/ml
0 50
0
0
0-25
1-13
0-38
1-63
0-38
0-25
0-13
0-10
0
0
80 ,ug/ml
1-88
1-38
0 50
0-88
0 75
0-25
0- 75
0-38
0-75
0-25
0-16
0
0
40 ,ug/ml
1-76
0-50
1-13
0- 75
0-75
0-25
0- 75
0-50
0- 75
0-13
0-06
0
0
20 ,ug/ml
1 -25
0-50
0-88
0-75
0-75
0
0-38
0-38
0-50
0-13
0
0
0
TABLE II.-Titration of Absorbed anti-C-71 at a Dilution of 1/50 with Individual
Tumour Extracts of Various Pathological Types
Pathological tumour type
Anaplastic
C-56
C-67
C-92
C-62
Oat cell
C-72
C-70
C-78
C-65
Adenocarcinoma
C-58
C-85
Alveolar
C-81
C-30
C'H5Ag+Ab at various antigen concentrations with
absorbed antiserum at 1/50
160 ug/ml 80 ,ug/ml 40 ,ug/ml 20 ,ug/ml
0-63
0
0
1 -25
0
0
0
1 -38
0
0-38
0-63
0-88
It is not clear at this time whether the
antigen being detected by this antiserum
is in fact tumour-specific or ifthe reaction
is showing only a quantitative difference
in a component(s) of both normal and
tumour tissue. The finding that all
individual squamous-cell extracts react
with this antiserum, whereas none of the
normal-tissue extracts, comprising pools
from 13 individuals, do not, make it
highly improbable that the antiserum is
directed to any specific histocompatibility
antigen. At present, it is impossible to
test the antigen preparations by the
0-75
0
0
0-50
0
0
0
1-38
0
0-50
0-13
0-88
0-50
0
0
0-50
0
0
0-75
0
1-63
0-38
1-75
0-50
0
0
0
0
0
0
0-63
0
1 -63
0-38
1 -13
complement-fixation assay at concentra-
tions of higher than 200 ,ug/ml, since at
these levels many of the preparations are
exceedingly anti-complementary. How-
ever, we are anticipating that this question
may be answered by subsequent studies
involving fractionation and purification of
components from both normal and
squamous-cell extracts, using the anti-
serum to monitor fractions for the pre-
sence of the antigen. The fact that the
test tumour extracts were from surgical
specimens, whereas the test normal ex-
tracts were made from tissue taken at
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autopsy, should also be noted in con-
sidering the significance of these findings.
Regarding this, it should be reiterated
that C-71, the tumour extract used as
immunogen, was in fact also an autopsy
specimen. We have also tested a number
of autopsy tumour-tissue extracts from
patients having died from squamous-cell
carcinoma, and in these instances positive
complement fixation was also observed
(data not shown). Surgical specimens
were used throughout the present study
for testing the antiserum, because we were
more certain regarding the time intervals
between removal of the tissue and its
subsequent extraction. Hence, these sam-
ples were considered to be more compar-
able. Current work has shown that the
anti-C-71 serum is not unique in any way,
and that antisera with similar specificities
can be raised using the same procedure
with other tumour extracts. Because
data on these antisera are still preli-
minary, they were not presented in this
report.
The possibility that our antisera were
detecting CEA in tumour extracts was
discounted for two reasons. CEA levels
were calculated on all extracts (both
normal and tumour) and no correlation
was seen between our complement-fixation
tests and CEA levels of test extracts.
Also, considerable levels of CEA (100
ng/ml) were detected in the normal
pooled lung extracts. Thus the anti-
normal-lung antisera injected simulta-
neously with tumour extract should have
suppressed an anti-CEA response, and the
glutaraldehyde-insolubilized normal-lung
immunoadsorbant should have effectively
removed any low levels of antibody to
CEA which might have been present in
the test sera.
In summary, the procedure described
here has a number of advantages and
applications over methods described pre-
viously. It may be applicable not only to
the preparation of relatively monospecific
reasonably titred xeno-antiserum to TAA,
so that these components may ultimately
be isolated, but also the preparation of
antisera to other human tissue com-
ponents such as HLA antigens or hormone
receptors. Further work in thislaboratory
will be toward obtaining definitive answers
to some of the implications presented by
these observations.
This work was supported by Grant
No. 65-6048 from the National Cancer
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